CTB-02

CTB-02 is an orally bioavailable, small-molecule pan-RAF inhibitor developed by Beijing Percans Oncology. It is designed to target and inhibit the activity of ARAF, BRAF (including the V600E mutation), and CRAF kinases within the MAPK/ERK signaling pathway. By inhibiting all three RAF isoforms, CTB-02 aims to suppress oncogenic signaling in tumors driven by BRAF mutations or KRAS mutations, potentially overcoming the paradoxical activation and resistance mechanisms associated with first-generation BRAF-selective inhibitors. It is currently being evaluated in Phase 1/2 clinical trials for the treatment of advanced solid tumors, including BRAF V600E-mutant colorectal cancer, KRAS-mutant colorectal cancer, and lung cancer.